Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     

  • Dow Jones

    37.986,40
    +211,02 (+0,56%)
     

  • Nasdaq

    15.282,01
    -319,49 (-2,05%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,24
    +0,51 (+0,62%)
     

  • Bitcoin EUR

    60.016,70
    +2.026,75 (+3,50%)
     

  • CMC Crypto 200

    1.371,97
    +59,34 (+4,52%)
     

  • Oro

    2.406,70
    +8,70 (+0,36%)
     

  • EUR/USD

    1,0661
    +0,0015 (+0,14%)
     

  • S&P 500

    4.967,23
    -43,89 (-0,88%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     

  • EUR/GBP

    0,8612
    +0,0056 (+0,65%)
     

  • EUR/CHF

    0,9693
    -0,0017 (-0,18%)
     

  • EUR/CAD

    1,4644
    -0,0007 (-0,05%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
·2 minuto per la lettura
Cellectis Inc.
Cellectis Inc.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting
rights

08/31/2022

45,550,810

51,615,672

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

ANNUNCIO PUBBLICITARIO

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment